Vanguard Therapeutics, Inc.

Half Moon Bay, CA 94019

SBIR Award Summary

Total Number of Awards 6
Total Value of Awards $4.21MM
First Award Date 02/15/14
Most Recent Award Date 09/21/17

Key Personnel

Last Name Name Awards Contact
EMBURY STEPHEN H. EMBURY 6

6 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-14-088
Budget: 09/21/17 - 08/31/18

Abstract Sickle cell disease (SCD) is a poorly treated, inherited, debilitating condition for which Vanguard Therapeutics, Inc. is developing a promising new long-term oral therapy. A dire need exists for our drug, as the millions of SCD patients worldwide and ~89,000 in the US continue to suffer with recurring pain episodes, disability, and pre...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-15-269
Budget: 09/01/17 - 08/31/18

Abstract Sickle cell disease (SCD) is a poorly treated, inherited, debilitating condition for which Vanguard Therapeutics, Inc. is developing a promising new long-term oral therapy. A dire need exists for our drug, as the millions of SCD patients worldwide and ~89,000 in the US continue to suffer with episodic pain episodes, disability, and prem...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-15-269
Budget: 09/19/16 - 08/31/17

Abstract Sickle cell disease (SCD) is a poorly treated, inherited, debilitating condition for which Vanguard Therapeutics, Inc. is developing a promising new long-term oral therapy. A dire need exists for our drug, as the millions of SCD patients worldwide and ~89,000 in the US continue to suffer with episodic pain episodes, disability, and prem...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-13-088
Budget: 05/15/15 - 07/31/15

DESCRIPTION (provided by applicant): Sickle cell disease (SCD) remains a poorly treated disease. Based on evidence that endothelial P-selectin is central to the abnormal microvascular blood flow in SCD, we are targeting this molecule with our therapy. Our in vitro and preliminary clinical data show that pentosan polysulfate sodium (PPS) improves...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-13-234
Budget: 08/01/14 - 01/31/15

DESCRIPTION (provided by applicant): Sickle cell disease (SCD) is a poorly treated debilitating condition for which we are developing a promising, new oral prophylactic therapy. A dire need exists for our drug, as millions of patients who have inherited SCD world-wide, ~100,000 in the US, continue to suffer with episod...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-13-088
Budget: 02/15/14 - 07/31/14

Sickle cell disease (SCD) remains a poorly treated disease. Based on evidence that endothelial P-selectin is central to the abnormal microvascular blood flow in SCD, we are targeting this molecule with our therapy. Our in vitro and preliminary clinical data show that pentosan polysulfate sodium (PPS) improves microvascular blood flow in SCD. How...